DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lipofen (Fenofibrate) - Drug Interactions, Contraindications, Overdosage, etc



Coumarin Anticoagulants

Potentiation of coumarin-type anticoagulant effect has been observed with prolongation of the PT/INR.

Caution should be exercised when LIPOFEN is given in conjunction with coumarin anticoagulants. LIPOFEN may potentiate the anticoagulant effect of these agents resulting in prolongation of the PT/INR. To prevent bleeding complications, frequent monitoring of PT/INR and dose adjustment of the oral anticoagulant as recommended until the PT/INR has stabilized [see Warnings and Precautions].


Immunosuppressant agents such as cyclosporine and tacrolimus can impair renal function and because renal excretion is the primary elimination route of fibrate drugs including LIPOFEN, there is a risk that an interaction will lead to deterioration of renal function. When immunosuppressants and other potentially nephrotoxic agents are co-administered with LIPOFEN, the lowest effective dose of LIPOFEN should be employed and renal function should be monitored.

Bile-Acid Binding Resins

Since bile-acid binding resins may bind other drugs given concurrently, patients should take LIPOFEN at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption.


Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.


There is no specific treatment for overdose with LIPOFEN. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an overdose occur. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. The usual precautions should be observed to maintain the airway. Because fenofibrate is highly bound to plasma proteins, hemodialysis should not be considered.


LIPOFEN is contraindicated in:

  • patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology ].
  • patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions].
  • patients with preexisting gallbladder disease [see Warnings and Precautions ].
  • patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions(5.9)].
  • nursing mothers [see Use in Specific Populations].

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017